<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025q4/ffd-2025q4.xsd"
      xlink:type="simple"/>
    <context id="rc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
        </entity>
        <period>
            <startDate>2026-11-04</startDate>
            <endDate>2026-11-04</endDate>
        </period>
    </context>
    <context id="offrl_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-11-04</startDate>
            <endDate>2026-11-04</endDate>
        </period>
    </context>
    <context id="offrl_2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001668243</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>2</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-11-04</startDate>
            <endDate>2026-11-04</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <ffd:FormTp contextRef="rc" id="ixv-116">S-8</ffd:FormTp>
    <ffd:SubmissnTp contextRef="rc" id="ixv-117">S-8</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="rc" id="ixv-118">EX-FILING FEES</ffd:FeeExhibitTp>
    <dei:EntityCentralIndexKey contextRef="rc" id="ixv-119">0001668243</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-120">UroGen Pharma Ltd.</dei:EntityRegistrantName>
    <ffd:OfferingTableNa contextRef="rc" id="hiddenrcOfferingTableNa" xsi:nil="true"/>
    <ffd:OffsetTableNa contextRef="rc" id="hiddenrcOffsetTableNa">N/A</ffd:OffsetTableNa>
    <ffd:CombinedProspectusTableNa contextRef="rc" id="hiddenrcCombinedProspectusTableNa">N/A</ffd:CombinedProspectusTableNa>
    <ffd:FormTp contextRef="rc" id="ixv-121">S-8</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="rc" id="ixv-122">UroGen Pharma Ltd.</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg contextRef="offrl_1" id="ixv-123">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="offrl_1" id="ixv-124">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_1" id="ixv-125">Ordinary Shares, par value NIS 0.01 per share, to be issued pursuant to future awards under the UroGen Pharma Ltd. 2017 Equity Incentive Plan</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="offrl_1" id="ixv-126">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="offrl_1"
      decimals="0"
      id="ixv-127"
      unitRef="Shares">1000000</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="offrl_1"
      decimals="2"
      id="ixv-128"
      unitRef="USD">33.02</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="offrl_1"
      decimals="2"
      id="ixv-129"
      unitRef="USD">33020000.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="offrl_1"
      decimals="7"
      id="ixv-130"
      unitRef="pure">0.0000870</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="offrl_1"
      decimals="2"
      id="ixv-131"
      unitRef="USD">2872.74</ffd:FeeAmt>
    <ffd:PrevslyPdFlg contextRef="offrl_2" id="ixv-132">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="offrl_2" id="ixv-133">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="offrl_2" id="ixv-134">Ordinary Shares, par value NIS 0.01 per share, to be issued pursuant to future awards under the UroGen Pharma Ltd. 2019 Inducement Plan</ffd:OfferingSctyTitl>
    <ffd:FeesOthrRuleFlg contextRef="offrl_2" id="ixv-135">true</ffd:FeesOthrRuleFlg>
    <ffd:AmtSctiesRegd
      contextRef="offrl_2"
      decimals="0"
      id="ixv-136"
      unitRef="Shares">600000</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="offrl_2"
      decimals="2"
      id="ixv-137"
      unitRef="USD">33.02</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="offrl_2"
      decimals="2"
      id="ixv-138"
      unitRef="USD">19812000.00</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="offrl_2"
      decimals="7"
      id="ixv-139"
      unitRef="pure">0.0000870</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="offrl_2"
      decimals="2"
      id="ixv-140"
      unitRef="USD">1723.64</ffd:FeeAmt>
    <ffd:TtlOfferingAmt contextRef="rc" decimals="2" id="ixv-141" unitRef="USD">52832000.00</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt contextRef="rc" decimals="2" id="ixv-142" unitRef="USD">4596.38</ffd:TtlFeeAmt>
    <ffd:TtlPrevslyPdAmt contextRef="rc" decimals="2" id="ixv-143" unitRef="USD">0.00</ffd:TtlPrevslyPdAmt>
    <ffd:TtlOffsetAmt contextRef="rc" decimals="2" id="ixv-144" unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt contextRef="rc" decimals="2" id="ixv-145" unitRef="USD">4596.38</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="offrl_1" id="ixv-146">Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional ordinary shares ("Ordinary Shares") of UroGen Pharma Ltd. (the "Registrant") that become issuable under the Registrant's 2017 Equity Incentive Plan, as amended (the "2017 Plan") and the Registrant's 2019 Inducement Plan, as amended (the "Inducement Plan") by reason of any stock dividend, stock split, recapitalization or other similar transaction. The amount registered represents (i) Ordinary Shares authorized for issuance under the 2017 Plan pursuant to an amendment to such plan that was approved by the Registrant's shareholders on June 22, 2026 and (ii) Ordinary Shares authorized for issuance under the Inducement Plan pursuant to an amendment to such plan that was approved by the Registrant's Board of Directors on September 14, 2026. The Inducement Plan was approved by the Registrant's Board of Directors without shareholder approval pursuant to Nasdaq Listing Rule 5635(c)(4). The proposed maximum aggregate offering price per unit and the proposed maximum aggregate offering price for the 1,000,000 Ordinary Shares and 600,0000 Ordinary Shares reserved for future grant under the 2017 Plan and the Inducement Plan, respectively, are made pursuant to Rule 457(c) and Rule 457(h)(1) of the Securities Act solely for the purpose of calculating the registration fee, and are based upon the average of the high and low prices of the Ordinary Shares on October 30, 2026, as reported on the Nasdaq Global Market. </ffd:OfferingNote>
    <ffd:OfferingNote contextRef="offrl_2" id="ixv-147">Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional ordinary shares ("Ordinary Shares") of UroGen Pharma Ltd. (the "Registrant") that become issuable under the Registrant's 2017 Equity Incentive Plan, as amended (the "2017 Plan") and the Registrant's 2019 Inducement Plan, as amended (the "Inducement Plan") by reason of any stock dividend, stock split, recapitalization or other similar transaction. The amount registered represents (i) Ordinary Shares authorized for issuance under the 2017 Plan pursuant to an amendment to such plan that was approved by the Registrant's shareholders on June 22, 2026 and (ii) Ordinary Shares authorized for issuance under the Inducement Plan pursuant to an amendment to such plan that was approved by the Registrant's Board of Directors on September 14, 2026. The Inducement Plan was approved by the Registrant's Board of Directors without shareholder approval pursuant to Nasdaq Listing Rule 5635(c)(4). The proposed maximum aggregate offering price per unit and the proposed maximum aggregate offering price for the 1,000,000 Ordinary Shares and 600,0000 Ordinary Shares reserved for future grant under the 2017 Plan and the Inducement Plan, respectively, are made pursuant to Rule 457(c) and Rule 457(h)(1) of the Securities Act solely for the purpose of calculating the registration fee, and are based upon the average of the high and low prices of the Ordinary Shares on October 30, 2026, as reported on the Nasdaq Global Market. </ffd:OfferingNote>
</xbrl>
